Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: hotlinktuna who wrote (52292)	12/18/2005 5:18:40 PM
From: gulleyjimson	Read Replies (1) \| Respond to of 59879

EECP's been around a long time. Vaso keeps reissuing the news and the stock keeps going down. Be careful out there. From 2001: WESTBURY, NY (September 7, 2001) – Vasomedical, Inc. (Nasdaq: VASO) announced today that a study presented this week during the 23rd Scientific Sessions of the European Society of Cardiology in Stockholm, Sweden, concluded that EECP® enhanced external counterpulsation is as effective in reducing angina in patients who are eighty years of age or older as it is for those who are younger. Octogenarians undergoing cardiac bypass surgery or percutaneous coronary interventions, such as angioplasty and stenting, have higher in-hospital mortality and morbidity than younger patients. The study, entitled Enhanced external counterpulsation for the treatment of angina in the elderly: safety, response and durability of benefit and presented by Georgiann Linnemeier, MD, Medical Director of HeartGen Centers in Indianapolis, looked at 3,037 patients consecutively enrolled in the International EECP® Patient Registry maintained by the University of Pittsburgh Graduate School of Public Health's Department of Epidemiology. The study compared the outcomes of 249 patients eighty years of age or older to 2,788 patients under the age of eighty. Results of the analysis showed that 76% of patients over eighty and 82% of patients younger than eighty reported a reduction in angina by one or more classes immediately following a full course of EECP treatment and that this benefit was maintained in over eighty percent of these patients at six months post-treatment. A majority of patients in both groups also reported an improvement in their quality of life. vasomedical.com